Study S001267

A Phase 2, Randomized, Triple-Blind, Placebo-Controlled, Multicenter Study to Examine the Effect of Exenatide Monotherapy on Glucose Control in Subjects With Type 2 Diabetes Mellitus

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT00085969
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: DOUBLE
Status: COMPLETED
Enrollment: 99
Start: 2003-09
Primary completion: 2004-01
Lead sponsor: AstraZeneca
Conditions: Diabetes Mellitus, Type 2
Interventions: DRUG:Placebo 0.04 mL twice daily; DRUG:Placebo 0.04 mL once daily; DRUG:Placebo 0.08 mL once daily; DRUG:B - Exenatide 10 mcg twice daily; DRUG:C - Exenatide 10 mcg once daily; DRUG:Exenatide 20 mcg once daily
Results posted: FALSE

Registered primary outcomes

Change in HbA1c (glycosylated hemoglobin) from Baseline to Day 28 [Baseline, Day 28]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0025690	The incretin mimetic exenatide as a monotherapy in patients with type 2 diabetes. Nelson P, Diabetes technology & therapeutics	2007	Randomized trial	PMID 17705687 DOI	cites ClinicalTrials.gov:NCT00085969; registry reference DERIVED:17705687